Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 9:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 4,699 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Active Control Condition Clear all
Terminated Phase 3 Interventional

A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease

NCT06307613
View directory record Official record
Conditions
Thyroid Eye Disease
Interventions
Efgartigimod PH20 SC, Placebo PH20 SC
Combination Product · Other
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
16
States / cities
Beverly Hills, California • Irvine, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 17, 2026, 9:30 PM EDT
Recruiting Phase 2 Interventional

SARS-CoV-2 Specific Monoclonal Antibody for Post-COVID-19 Conditions (Long COVID)

NCT07021794
View directory record Official record
Conditions
Post-COVID / Long-COVID
Interventions
Placebo, Sipavibart
Drug · Biological
Lead sponsor
Nancy Klimas
Other
Eligibility
18 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Fort Lauderdale, Florida
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 17, 2026, 9:30 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Evaluation of Thiwáhe Gluwáš'Akapi Substance Use Prevention Program

NCT04222556
View directory record Official record
Conditions
Substance Use, Substance Abuse, Suicide
Interventions
Thiwáhe Gluwáš'akapi, Woyute Waśte
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
10 Years to 85 Years
Enrollment
552 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 22, 2023 · Synced Oct 17, 2026, 9:30 PM EDT
Completed Phase 2 Interventional Results available

Novel Medication Strategies Targeting Brain Mechanisms in Pediatric OCD

NCT01695291
View directory record Official record
Conditions
Obsessive Compulsive Disorder
Interventions
Minocycline, Placebo
Drug · Other
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
8 Years to 20 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 13, 2019 · Synced Oct 17, 2026, 9:30 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

SHIELD Study: Using Naso-oropharyngeal Antiseptic Decolonization to Reduce COVID-19 Viral Shedding

NCT04478019
View directory record Official record
Conditions
COVID-19, SARS-CoV 2
Interventions
10% Povidone-iodine nasal decolonization swab plus 0.12% CHG oral rinse
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
245 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 14, 2022 · Synced Oct 17, 2026, 9:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Relative Bioavailability Study of Alprazolam 3 mg Extended Release Tablets Under Non-fasting Conditions

NCT00865657
View directory record Official record
Conditions
Healthy
Interventions
Alprazolam 3 mg Extended Release Tablets, single dose, XANAX XR® 3 mg tablets, single dose
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Aug 17, 2010 · Synced Oct 17, 2026, 9:30 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Sustaining Aviator Performance During Extended Operational Flight

NCT04697901
View directory record Official record
Conditions
Transcranial Direct Current Stimulation
Interventions
Active Transcranial Direct Current Stimulation (tDCS), Sham Transcranial Direct Current Stimulation (tDCS)
Device
Lead sponsor
United States Army Aeromedical Research Laboratory
Federal
Eligibility
18 Years to 40 Years · Male only
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Fort Rucker, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 25, 2022 · Synced Oct 17, 2026, 9:30 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Project EMPOWER-OCD

NCT07158801
View directory record Official record
Conditions
Obsessive-Compulsive Disorder
Interventions
Project EMPOWER-OCD, Project CARE
Behavioral
Lead sponsor
Boston University Charles River Campus
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 17, 2026, 9:30 PM EDT
Completed Phase 3 Interventional

Testing the Effectiveness of a Computer-based Program for Depression

NCT01203683
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Active computer-based training, Inert computer training
Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years to 55 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 10, 2013 · Synced Oct 17, 2026, 9:30 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Post-Marketing Safety Study of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in the United States

NCT04958954
View directory record Official record
Conditions
SARS-CoV-2
Interventions
Not listed
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
Not listed
Enrollment
50,000,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 17, 2023 · Synced Oct 17, 2026, 9:30 PM EDT
Completed Not applicable Interventional Results available

Process-instructed Self Neuro-Modulation (PRISM) for Attention Deficit/ Hyperactivity Disorder - Adults

NCT04640766
View directory record Official record
Conditions
Attention Deficit Hyper Activity
Interventions
PRISM
Device
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 60 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Oct 17, 2026, 9:30 PM EDT
Terminated Phase 1 Interventional

Itacitinib and Tocilizumab for Steroid Refractory Acute Graft Versus Host Disease

NCT04070781
View directory record Official record
Conditions
Steroid Refractory GVHD, Graft Vs Host Disease
Interventions
Itacitinib, Tocilizumab
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 99 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 4, 2024 · Synced Oct 17, 2026, 9:30 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use Disorder

NCT05452772
View directory record Official record
Conditions
Tobacco Use Disorder
Interventions
Psilocybin, Niacin
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years and older
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
3
States / cities
Birmingham, Alabama • Baltimore, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 17, 2026, 9:30 PM EDT
Completed Not applicable Interventional Results available

Comparing Early Capsule Deployment to Current Standard of Care for Management of Gastrointestinal Bleeding

NCT02442830
View directory record Official record
Conditions
Melena, Gastrointestinal Hemorrhage
Interventions
Early Video Capsule Endoscopy
Device
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 7, 2018 · Synced Oct 17, 2026, 9:30 PM EDT
Completed Phase 3 Interventional Results available

Revefenacin Peak Inspiratory Flow Rate (PIFR) Study in COPD

NCT03095456
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, COPD, Low Peak Inspiratory Flow Rate (PIFR)
Interventions
Revefenacin, Spiriva Handihaler®, Placebo for Revefenacin, Placebo for Spiriva Handihaler®
Drug · Combination Product
Lead sponsor
Mylan Inc.
Industry
Eligibility
40 Years and older
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Rock Hill, South Carolina
Source: ClinicalTrials.gov public record
Updated Feb 24, 2022 · Synced Oct 17, 2026, 9:30 PM EDT
Completed Not applicable Interventional

G.R.I.T. - Goal-directed Resilience Intervention Training

NCT03890029
View directory record Official record
Conditions
Chronic Post-Traumatic Stress Disorder
Interventions
Intervention Training, Control Condition
Behavioral
Lead sponsor
Morehouse School of Medicine
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 16, 2023 · Synced Oct 17, 2026, 9:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Limited Food Effect Study of Gabapentin 800 mg Tablets

NCT00865631
View directory record Official record
Conditions
Healthy
Interventions
Gabapentin 800 mg tablets, single dose (1 tablet), NEURONTIN® 400 mg capsules, single dose (2 capsules)
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Aug 17, 2010 · Synced Oct 17, 2026, 9:30 PM EDT
Terminated Not applicable Interventional

Use of tAN® in Alcohol Withdrawal Management

NCT06771037
View directory record Official record
Conditions
Alcohol Withdrawal
Interventions
Transcutaneous Auricular Neurostimulation (tAN)
Device
Lead sponsor
Erin Takemoto
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Wernersville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 17, 2026, 9:30 PM EDT
Completed Phase 3 Interventional Results available

Adult Attention Deficit Hyperactivity Disorder (ADHD) Study With Amphetamine Sulfate

NCT03659929
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Amphetamine Sulfate, Placebo
Drug
Lead sponsor
Arbor Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
31
States / cities
Encino, California • Garden Grove, California • Newport Beach, California + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2024 · Synced Oct 17, 2026, 9:30 PM EDT
Completed Phase 3 Interventional Results available

Comparison of Tiotropium in the HandiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease

NCT01126437
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
tiotropium 18 mcg, tiotropium 1.25 mcg (2 actuations/day), tiotropium 2.5 mcg (2 actuations/day)
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
17,183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
303
States / cities
Athens, Alabama • Birmingham, Alabama • Florence, Alabama + 243 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2014 · Synced Oct 17, 2026, 9:30 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study to Evaluate Administration of SBT101 Gene Therapy in Adult Patients With Adrenomyeloneuropathy (AMN)

NCT05394064
View directory record Official record
Conditions
AMN, AMN Gene Mutation, X-ALD
Interventions
SBT101 Treatment
Genetic
Lead sponsor
SwanBio Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 17, 2026, 9:30 PM EDT
Terminated Phase 1 Interventional

Study of Intramuscular Injections of ABBV-950 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Upper Limb Spasticity

NCT05956509
View directory record Official record
Conditions
Upper Limb Spasticity
Interventions
ABBV-950, BOTOX, Placebo for ABBV-950
Biological · Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 80 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
9
States / cities
Carlsbad, California • Downey, California • Fresno, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2024 · Synced Oct 17, 2026, 9:30 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors

NCT04875806
View directory record Official record
Conditions
Advanced or Metastatic Solid Tumors, Ovarian Cancer, Non-small Cell Lung Cancer, Breast Cancer
Interventions
NC762
Drug
Lead sponsor
NextCure, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
8
States / cities
New Haven, Connecticut • Chicago, Illinois • Hackensack, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2025 · Synced Oct 17, 2026, 9:30 PM EDT
Completed Phase 2Phase 3 Interventional Results available

26 Week Efficacy, Safety and Tolerability Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT00463567
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, COPD, Lung Diseases, Obstructive
Interventions
Indacaterol, Formoterol (12 µg b.i.d.), Tiotropium (18 µg o.d.), Placebo to Indacaterol, Placebo to Formoterol
Drug
Lead sponsor
Novartis
Industry
Eligibility
40 Years and older
Enrollment
2,059 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
221
States / cities
Anniston, Alabama • Birmingham, Alabama • Homewood, Alabama + 163 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2011 · Synced Oct 17, 2026, 9:30 PM EDT